Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab.

Antibodies, Monoclonal, Humanized / adverse effects Fingolimod Hydrochloride / adverse effects Humans Lymphopenia / chemically induced Multiple Sclerosis / drug therapy Retrospective Studies

Journal

Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388

Informations de publication

Date de publication:
05 2022
Historique:
received: 19 07 2021
accepted: 11 01 2022
entrez: 11 3 2022
pubmed: 12 3 2022
medline: 16 4 2022
Statut: epublish

Résumé

To investigate the longitudinal dynamic of lymphocyte subsets during treatment with ocrelizumab (OCR) in patients with multiple sclerosis (PwMS). A multicenter retrospective study was conducted in 161 PwMS starting treatment with OCR grouped in naive (naive, n = 40), switching from fingolimod (FTY, n = 52), and switching from other immunomodulating drugs (other, n = 69). Mean lymphocyte subset (total, CD3 Mean total, CD3 OCR per se exerts a modest depleting effect on T cells that seems rather due to a carryover phenomenon of previous therapies, particularly FTY. These data may help in the overall evaluation of the risk/benefit profile of treatment sequencing.

Sections du résumé

BACKGROUND AND OBJECTIVES
To investigate the longitudinal dynamic of lymphocyte subsets during treatment with ocrelizumab (OCR) in patients with multiple sclerosis (PwMS).
METHODS
A multicenter retrospective study was conducted in 161 PwMS starting treatment with OCR grouped in naive (naive, n = 40), switching from fingolimod (FTY, n = 52), and switching from other immunomodulating drugs (other, n = 69). Mean lymphocyte subset (total, CD3
RESULTS
Mean total, CD3
DISCUSSION
OCR per se exerts a modest depleting effect on T cells that seems rather due to a carryover phenomenon of previous therapies, particularly FTY. These data may help in the overall evaluation of the risk/benefit profile of treatment sequencing.

Identifiants

DOI: 10.1212/NXI.0000000000001157 PMID: 35273036 PMC: PMC9005049
pubmed: 35273036
pii: 9/3/e1157
doi: 10.1212/NXI.0000000000001157
pmc: PMC9005049
pii:
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
ocrelizumab A10SJL62JY
Fingolimod Hydrochloride G926EC510T

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Références

Cells. 2018 Dec 28;8(1):
pubmed: 30597851
Curr Neurol Neurosci Rep. 2017 Aug;17(8):61
pubmed: 28669032
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Mult Scler. 2022 Jan;28(1):93-101
pubmed: 33855897
Neurol Neuroimmunol Neuroinflamm. 2021 Jan 6;8(2):
pubmed: 33408167
Mult Scler. 2015 May;21(6):726-34
pubmed: 25392322
Ann N Y Acad Sci. 2005 Jun;1051:255-62
pubmed: 16126966
Neurology. 2008 Oct 14;71(16):1261-7
pubmed: 18852441
Arthritis Rheum. 2009 Dec;60(12):3563-71
pubmed: 19950291
J Clin Neurosci. 2019 May;63:91-94
pubmed: 30772201
Neurol Neuroimmunol Neuroinflamm. 2020 Aug 14;7(6):
pubmed: 32801166
J Neurol. 2021 Jun;268(6):2238-2245
pubmed: 33496861
J Immunol. 2016 Aug 15;197(4):1111-7
pubmed: 27412413
Mult Scler. 2017 Aug;23(9):1225-1232
pubmed: 28749311

Auteurs

Doriana Landi (D)

From the Multiple Sclerosis Research and Clinical Unit (D.L., A.G., G.C., C.G.N., G.M., G.A.M.); Department of Systems Medicine (D.L., G.C., C.G.N., G.M., D.C., G.A.M.), Tor Vergata University, Rome; Department of Health Sciences (DISSAL) (F. Bovis, M.P.), University of Genoa; Unit of Neurology and Neurorehabilitation (R.F., F. Buttari, D.C., G.A.M.), IRCCS Neuromed, Pozzilli; Multiple Sclerosis Center (E.S., G.L.), Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples; Multiple Sclerosis Center (M.L., M.M.), Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome; Università Cattolica Del Sacro Cuore (M.L., M.M.), CERSM, Rome; Department of Neuroscience (M.C., M.I.), Rehabilitation, Maternal and Child Health (DINOGMI), University of Genoa; and IRCCS Ospedale Policlinico San Martino (M.I.), Genoa, Italy.
ORCID: 0000-0002-3309-8417

Alfonso Grimaldi (A)

From the Multiple Sclerosis Research and Clinical Unit (D.L., A.G., G.C., C.G.N., G.M., G.A.M.); Department of Systems Medicine (D.L., G.C., C.G.N., G.M., D.C., G.A.M.), Tor Vergata University, Rome; Department of Health Sciences (DISSAL) (F. Bovis, M.P.), University of Genoa; Unit of Neurology and Neurorehabilitation (R.F., F. Buttari, D.C., G.A.M.), IRCCS Neuromed, Pozzilli; Multiple Sclerosis Center (E.S., G.L.), Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples; Multiple Sclerosis Center (M.L., M.M.), Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome; Università Cattolica Del Sacro Cuore (M.L., M.M.), CERSM, Rome; Department of Neuroscience (M.C., M.I.), Rehabilitation, Maternal and Child Health (DINOGMI), University of Genoa; and IRCCS Ospedale Policlinico San Martino (M.I.), Genoa, Italy.

Francesca Bovis (F)

From the Multiple Sclerosis Research and Clinical Unit (D.L., A.G., G.C., C.G.N., G.M., G.A.M.); Department of Systems Medicine (D.L., G.C., C.G.N., G.M., D.C., G.A.M.), Tor Vergata University, Rome; Department of Health Sciences (DISSAL) (F. Bovis, M.P.), University of Genoa; Unit of Neurology and Neurorehabilitation (R.F., F. Buttari, D.C., G.A.M.), IRCCS Neuromed, Pozzilli; Multiple Sclerosis Center (E.S., G.L.), Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples; Multiple Sclerosis Center (M.L., M.M.), Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome; Università Cattolica Del Sacro Cuore (M.L., M.M.), CERSM, Rome; Department of Neuroscience (M.C., M.I.), Rehabilitation, Maternal and Child Health (DINOGMI), University of Genoa; and IRCCS Ospedale Policlinico San Martino (M.I.), Genoa, Italy.
ORCID: 0000-0002-3823-4000

Marta Ponzano (M)

From the Multiple Sclerosis Research and Clinical Unit (D.L., A.G., G.C., C.G.N., G.M., G.A.M.); Department of Systems Medicine (D.L., G.C., C.G.N., G.M., D.C., G.A.M.), Tor Vergata University, Rome; Department of Health Sciences (DISSAL) (F. Bovis, M.P.), University of Genoa; Unit of Neurology and Neurorehabilitation (R.F., F. Buttari, D.C., G.A.M.), IRCCS Neuromed, Pozzilli; Multiple Sclerosis Center (E.S., G.L.), Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples; Multiple Sclerosis Center (M.L., M.M.), Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome; Università Cattolica Del Sacro Cuore (M.L., M.M.), CERSM, Rome; Department of Neuroscience (M.C., M.I.), Rehabilitation, Maternal and Child Health (DINOGMI), University of Genoa; and IRCCS Ospedale Policlinico San Martino (M.I.), Genoa, Italy.

Roberta Fantozzi (R)

From the Multiple Sclerosis Research and Clinical Unit (D.L., A.G., G.C., C.G.N., G.M., G.A.M.); Department of Systems Medicine (D.L., G.C., C.G.N., G.M., D.C., G.A.M.), Tor Vergata University, Rome; Department of Health Sciences (DISSAL) (F. Bovis, M.P.), University of Genoa; Unit of Neurology and Neurorehabilitation (R.F., F. Buttari, D.C., G.A.M.), IRCCS Neuromed, Pozzilli; Multiple Sclerosis Center (E.S., G.L.), Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples; Multiple Sclerosis Center (M.L., M.M.), Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome; Università Cattolica Del Sacro Cuore (M.L., M.M.), CERSM, Rome; Department of Neuroscience (M.C., M.I.), Rehabilitation, Maternal and Child Health (DINOGMI), University of Genoa; and IRCCS Ospedale Policlinico San Martino (M.I.), Genoa, Italy.

Fabio Buttari (F)

From the Multiple Sclerosis Research and Clinical Unit (D.L., A.G., G.C., C.G.N., G.M., G.A.M.); Department of Systems Medicine (D.L., G.C., C.G.N., G.M., D.C., G.A.M.), Tor Vergata University, Rome; Department of Health Sciences (DISSAL) (F. Bovis, M.P.), University of Genoa; Unit of Neurology and Neurorehabilitation (R.F., F. Buttari, D.C., G.A.M.), IRCCS Neuromed, Pozzilli; Multiple Sclerosis Center (E.S., G.L.), Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples; Multiple Sclerosis Center (M.L., M.M.), Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome; Università Cattolica Del Sacro Cuore (M.L., M.M.), CERSM, Rome; Department of Neuroscience (M.C., M.I.), Rehabilitation, Maternal and Child Health (DINOGMI), University of Genoa; and IRCCS Ospedale Policlinico San Martino (M.I.), Genoa, Italy.

Elisabetta Signoriello (E)

From the Multiple Sclerosis Research and Clinical Unit (D.L., A.G., G.C., C.G.N., G.M., G.A.M.); Department of Systems Medicine (D.L., G.C., C.G.N., G.M., D.C., G.A.M.), Tor Vergata University, Rome; Department of Health Sciences (DISSAL) (F. Bovis, M.P.), University of Genoa; Unit of Neurology and Neurorehabilitation (R.F., F. Buttari, D.C., G.A.M.), IRCCS Neuromed, Pozzilli; Multiple Sclerosis Center (E.S., G.L.), Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples; Multiple Sclerosis Center (M.L., M.M.), Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome; Università Cattolica Del Sacro Cuore (M.L., M.M.), CERSM, Rome; Department of Neuroscience (M.C., M.I.), Rehabilitation, Maternal and Child Health (DINOGMI), University of Genoa; and IRCCS Ospedale Policlinico San Martino (M.I.), Genoa, Italy.

Giacomo Lus (G)

From the Multiple Sclerosis Research and Clinical Unit (D.L., A.G., G.C., C.G.N., G.M., G.A.M.); Department of Systems Medicine (D.L., G.C., C.G.N., G.M., D.C., G.A.M.), Tor Vergata University, Rome; Department of Health Sciences (DISSAL) (F. Bovis, M.P.), University of Genoa; Unit of Neurology and Neurorehabilitation (R.F., F. Buttari, D.C., G.A.M.), IRCCS Neuromed, Pozzilli; Multiple Sclerosis Center (E.S., G.L.), Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples; Multiple Sclerosis Center (M.L., M.M.), Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome; Università Cattolica Del Sacro Cuore (M.L., M.M.), CERSM, Rome; Department of Neuroscience (M.C., M.I.), Rehabilitation, Maternal and Child Health (DINOGMI), University of Genoa; and IRCCS Ospedale Policlinico San Martino (M.I.), Genoa, Italy.

Matteo Lucchini (M)

From the Multiple Sclerosis Research and Clinical Unit (D.L., A.G., G.C., C.G.N., G.M., G.A.M.); Department of Systems Medicine (D.L., G.C., C.G.N., G.M., D.C., G.A.M.), Tor Vergata University, Rome; Department of Health Sciences (DISSAL) (F. Bovis, M.P.), University of Genoa; Unit of Neurology and Neurorehabilitation (R.F., F. Buttari, D.C., G.A.M.), IRCCS Neuromed, Pozzilli; Multiple Sclerosis Center (E.S., G.L.), Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples; Multiple Sclerosis Center (M.L., M.M.), Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome; Università Cattolica Del Sacro Cuore (M.L., M.M.), CERSM, Rome; Department of Neuroscience (M.C., M.I.), Rehabilitation, Maternal and Child Health (DINOGMI), University of Genoa; and IRCCS Ospedale Policlinico San Martino (M.I.), Genoa, Italy.
ORCID: 0000-0002-0447-2297

Massimiliano Mirabella (M)

From the Multiple Sclerosis Research and Clinical Unit (D.L., A.G., G.C., C.G.N., G.M., G.A.M.); Department of Systems Medicine (D.L., G.C., C.G.N., G.M., D.C., G.A.M.), Tor Vergata University, Rome; Department of Health Sciences (DISSAL) (F. Bovis, M.P.), University of Genoa; Unit of Neurology and Neurorehabilitation (R.F., F. Buttari, D.C., G.A.M.), IRCCS Neuromed, Pozzilli; Multiple Sclerosis Center (E.S., G.L.), Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples; Multiple Sclerosis Center (M.L., M.M.), Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome; Università Cattolica Del Sacro Cuore (M.L., M.M.), CERSM, Rome; Department of Neuroscience (M.C., M.I.), Rehabilitation, Maternal and Child Health (DINOGMI), University of Genoa; and IRCCS Ospedale Policlinico San Martino (M.I.), Genoa, Italy.

Maria Cellerino (M)

From the Multiple Sclerosis Research and Clinical Unit (D.L., A.G., G.C., C.G.N., G.M., G.A.M.); Department of Systems Medicine (D.L., G.C., C.G.N., G.M., D.C., G.A.M.), Tor Vergata University, Rome; Department of Health Sciences (DISSAL) (F. Bovis, M.P.), University of Genoa; Unit of Neurology and Neurorehabilitation (R.F., F. Buttari, D.C., G.A.M.), IRCCS Neuromed, Pozzilli; Multiple Sclerosis Center (E.S., G.L.), Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples; Multiple Sclerosis Center (M.L., M.M.), Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome; Università Cattolica Del Sacro Cuore (M.L., M.M.), CERSM, Rome; Department of Neuroscience (M.C., M.I.), Rehabilitation, Maternal and Child Health (DINOGMI), University of Genoa; and IRCCS Ospedale Policlinico San Martino (M.I.), Genoa, Italy.
ORCID: 0000-0002-4359-9872

Matilde Inglese (M)

From the Multiple Sclerosis Research and Clinical Unit (D.L., A.G., G.C., C.G.N., G.M., G.A.M.); Department of Systems Medicine (D.L., G.C., C.G.N., G.M., D.C., G.A.M.), Tor Vergata University, Rome; Department of Health Sciences (DISSAL) (F. Bovis, M.P.), University of Genoa; Unit of Neurology and Neurorehabilitation (R.F., F. Buttari, D.C., G.A.M.), IRCCS Neuromed, Pozzilli; Multiple Sclerosis Center (E.S., G.L.), Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples; Multiple Sclerosis Center (M.L., M.M.), Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome; Università Cattolica Del Sacro Cuore (M.L., M.M.), CERSM, Rome; Department of Neuroscience (M.C., M.I.), Rehabilitation, Maternal and Child Health (DINOGMI), University of Genoa; and IRCCS Ospedale Policlinico San Martino (M.I.), Genoa, Italy.

Gaia Cola (G)

From the Multiple Sclerosis Research and Clinical Unit (D.L., A.G., G.C., C.G.N., G.M., G.A.M.); Department of Systems Medicine (D.L., G.C., C.G.N., G.M., D.C., G.A.M.), Tor Vergata University, Rome; Department of Health Sciences (DISSAL) (F. Bovis, M.P.), University of Genoa; Unit of Neurology and Neurorehabilitation (R.F., F. Buttari, D.C., G.A.M.), IRCCS Neuromed, Pozzilli; Multiple Sclerosis Center (E.S., G.L.), Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples; Multiple Sclerosis Center (M.L., M.M.), Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome; Università Cattolica Del Sacro Cuore (M.L., M.M.), CERSM, Rome; Department of Neuroscience (M.C., M.I.), Rehabilitation, Maternal and Child Health (DINOGMI), University of Genoa; and IRCCS Ospedale Policlinico San Martino (M.I.), Genoa, Italy.

Carolina Gabri Nicoletti (CG)

From the Multiple Sclerosis Research and Clinical Unit (D.L., A.G., G.C., C.G.N., G.M., G.A.M.); Department of Systems Medicine (D.L., G.C., C.G.N., G.M., D.C., G.A.M.), Tor Vergata University, Rome; Department of Health Sciences (DISSAL) (F. Bovis, M.P.), University of Genoa; Unit of Neurology and Neurorehabilitation (R.F., F. Buttari, D.C., G.A.M.), IRCCS Neuromed, Pozzilli; Multiple Sclerosis Center (E.S., G.L.), Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples; Multiple Sclerosis Center (M.L., M.M.), Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome; Università Cattolica Del Sacro Cuore (M.L., M.M.), CERSM, Rome; Department of Neuroscience (M.C., M.I.), Rehabilitation, Maternal and Child Health (DINOGMI), University of Genoa; and IRCCS Ospedale Policlinico San Martino (M.I.), Genoa, Italy.

Giorgia Mataluni (G)

From the Multiple Sclerosis Research and Clinical Unit (D.L., A.G., G.C., C.G.N., G.M., G.A.M.); Department of Systems Medicine (D.L., G.C., C.G.N., G.M., D.C., G.A.M.), Tor Vergata University, Rome; Department of Health Sciences (DISSAL) (F. Bovis, M.P.), University of Genoa; Unit of Neurology and Neurorehabilitation (R.F., F. Buttari, D.C., G.A.M.), IRCCS Neuromed, Pozzilli; Multiple Sclerosis Center (E.S., G.L.), Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples; Multiple Sclerosis Center (M.L., M.M.), Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome; Università Cattolica Del Sacro Cuore (M.L., M.M.), CERSM, Rome; Department of Neuroscience (M.C., M.I.), Rehabilitation, Maternal and Child Health (DINOGMI), University of Genoa; and IRCCS Ospedale Policlinico San Martino (M.I.), Genoa, Italy.

Diego Centonze (D)

From the Multiple Sclerosis Research and Clinical Unit (D.L., A.G., G.C., C.G.N., G.M., G.A.M.); Department of Systems Medicine (D.L., G.C., C.G.N., G.M., D.C., G.A.M.), Tor Vergata University, Rome; Department of Health Sciences (DISSAL) (F. Bovis, M.P.), University of Genoa; Unit of Neurology and Neurorehabilitation (R.F., F. Buttari, D.C., G.A.M.), IRCCS Neuromed, Pozzilli; Multiple Sclerosis Center (E.S., G.L.), Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples; Multiple Sclerosis Center (M.L., M.M.), Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome; Università Cattolica Del Sacro Cuore (M.L., M.M.), CERSM, Rome; Department of Neuroscience (M.C., M.I.), Rehabilitation, Maternal and Child Health (DINOGMI), University of Genoa; and IRCCS Ospedale Policlinico San Martino (M.I.), Genoa, Italy.

Girolama Alessandra Marfia (GA)

From the Multiple Sclerosis Research and Clinical Unit (D.L., A.G., G.C., C.G.N., G.M., G.A.M.); Department of Systems Medicine (D.L., G.C., C.G.N., G.M., D.C., G.A.M.), Tor Vergata University, Rome; Department of Health Sciences (DISSAL) (F. Bovis, M.P.), University of Genoa; Unit of Neurology and Neurorehabilitation (R.F., F. Buttari, D.C., G.A.M.), IRCCS Neuromed, Pozzilli; Multiple Sclerosis Center (E.S., G.L.), Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples; Multiple Sclerosis Center (M.L., M.M.), Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome; Università Cattolica Del Sacro Cuore (M.L., M.M.), CERSM, Rome; Department of Neuroscience (M.C., M.I.), Rehabilitation, Maternal and Child Health (DINOGMI), University of Genoa; and IRCCS Ospedale Policlinico San Martino (M.I.), Genoa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Influence of Previous Disease-Modifying Drug...
questionsmedicales.fr › Composés chimiques organiques › Amines › Aminoalcools › Sphingosine › Chlorhydrate de fingolimod › Influence of Previous Disease-Modifying Drug...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Influence of Previous Disease-Modifying Drug...
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Lymphopénie › Influence of Previous Disease-Modifying Drug...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Maladies auto-immunes du système nerveux › Maladies démyélinisantes auto-immunes du SNC › Sclérose en plaques › Influence of Previous Disease-Modifying Drug...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Influence of Previous Disease-Modifying Drug...